SK Capital Partners


SK Capital Partners is an American private equity firm that invests in businesses with significant opportunities for improvement through its Flagship and Catalyst strategies, both of which focus on the middle market.

Utilizing company reviews written by actual employees at S&K Capital, you can gain more insight into its culture and working conditions.

SK Capital’s Approach to Investing

SK Capital is a private investment firm seeking companies with significant potential for business improvement. The firm typically pursues control buyout investments or recapitalizations in life sciences companies. Furthermore, growth equity financings may also be considered. On average, SK Capital typically invests up to $200 million worth of equity per transaction.

SK Capital’s team of experts boasts extensive industry, operating, and investment experience, enabling them to offer comprehensive support and guidance during portfolio company transformation processes. SK Capital commits itself to building resilient and sustainable businesses that create substantial long-term value for investors through targeted approaches and in-depth industry knowledge.

Ecopol, a Chiesina Uzzanese manufacturer of water-soluble and biodegradable films used in household detergent products, has entered into a strategic investment agreement with affiliates of private investment firm SK Capital Partners. Under this deal, Ecopol CEO and controlling shareholder Mauro Carbone will remain in his post and be its largest individual shareholder; existing minority investor Tikehau Capital also retains their shares in Ecopol.

Since 2007, this firm has been a premier provider of private equity capital to mid-sized and large industrial businesses, with expertise in specialty materials, ingredients, life sciences, and biopharma. Their portfolio companies generate over $17 billion in annual revenues while employing over 25,000 people globally and operating 200 plants in 30 different countries.

New York-based SK Capital Partners recently unveiled their latest fund, the SKCP Catalyst Fund II. The Fund received an oversubscription and reached its hard cap of $750 million with Limited Partner commitments and $50 million from SK as investment from their Firm. It specializes in lower middle market companies from specialty materials, ingredients, and life science sectors.

Zippia offers an in-depth profile of SK Capital Partners, including salary details, political affiliations, and employee data. This data comes from self-reported employees and past/current job advertisements on LinkedIn and public sources.

SK Capital’s Portfolio Companies

SK Capital invests in middle-market companies requiring up to $100 million of initial committed equity capital commitment. They specialize in control buyout investments, recapitalizations, and growth equity opportunities, working closely with management teams and developing strong relationships that support long-term strategic and financial goals.

SK Capital has made several investments in the life sciences sector, such as VanDeMark Chemical. VanDeMark Chemical is a premier provider of specialty building blocks derived from acceptable phosgene derivatives that serve multiple global customers across pharmaceuticals, polymers, electronics, coatings, and personal care industries. To serve this customer base, they maintain two manufacturing facilities located at Lockport, NY, and Kazincbarcika, Hungary.

SK Capital Partners, the private investment firm focused on specialty materials, ingredients, and life sciences sectors, has acquired a majority interest in Valtris Specialty Chemicals of Independence, Ohio – one of the premier manufacturers of specialty chemicals used for plastics, paints, adhesives, sealants, and pharmaceutical applications. Based in Independence, an annual production volume exceeds 1 billion pounds of product.

Funds advised by SK Capital Partners (“SK Capital”) have completed the sale of their interest in Perimeter Solutions, Inc. (“Perimeter” or the “Company”) to a group of investors led by Lincoln International; Moelis was Moelis’ sell-side advisor while Kirkland & Ellis provided legal counsel to Comvest as part of this transaction, structured as a leveraged buyout transaction. SK Capital invested through both Flagship and Catalyst strategies, which specialize in lower mid-sized markets, particularly this deal.

SK Capital’s Leadership Team

SK Capital’s leadership team comprises experienced professionals with diverse industry, operating, and investment expertise. This allows SK Capital to offer comprehensive support and guidance for portfolio companies navigating growth and transformation journeys.

Our firm invests in middle-market businesses across North America that possess significant potential for improvement and strong growth prospects. When selecting our investments, we consider various transaction scenarios such as buyouts, recapitalization, and growth equity financings.

SK Capital Partners maintains relationships with several other private equity firms and financial institutions that may open up additional opportunities for itself and its portfolio companies.

SK Capital Partners has assembled an experienced management team committed to optimizing its portfolio companies’ financial and operational performance. In particular, their expertise lies in driving organic growth while simultaneously improving operational efficiencies.

This combination of expertise enables SK Capital to identify and implement strategic investments that will accelerate growth while improving the financial performance of its portfolio companies. Beyond providing capital, SK Capital’s management team encourages collaboration and innovation within each portfolio company.

SK Capital’s team of specialists has in-depth knowledge of specialty materials and chemicals industries and has successfully transformed companies. Their breadth of experience provides a unique perspective on creating value in portfolio companies.

Over the past three years, SK Capital Partners has acquired 12 companies and invested in three more, with Perimeter Solutions accounting for their largest acquisition at $1.0B. Their most frequently targeted sectors for investment are chemicals (59%) and life science (14%).

SK Capital Partners is headquartered in New York City and employs approximately 550 full- and part-time employees, both full-time and part-time employees alike. Their average salary per job at SK Capital Partners is $106,864, which is higher than the national average across all job sectors. Pharmaceutical manufacturing was their top industry, paying an average salary of $142,090 per job.

SK Capital’s Investment Strategy

SK Capital is an investment firm committed to transforming businesses in the specialty materials, ingredients, and life sciences sectors. Targeted investing strategies and engagement with management teams help companies unlock their full potential and meet strategic and financial goals. Drawing upon its industry experience and multidisciplinary team expertise, they are well suited to identify and capitalize on unique investment opportunities.

Since 2007, SK Capital Partners has successfully raised seven funds totaling $7.8 billion across two segments – its flagship Flagship strategy and Catalyst funds – each targeting upper mid-sized and large company sectors, respectively, and lower middle markets.

SKCP recently closed their latest niche “Catalyst” strategy with an astounding hard cap of $750 million, significantly exceeding their initial committed equity capital commitment of $100 million. The SKCP Catalyst Fund II targets buyout investments that require initial committed equity capital of up to $100 million and will focus on specialty materials, ingredients, and life sciences businesses as targets.

SK Capital provides capital and expertise, assists portfolio companies through the transformation process, and offers ongoing value-added support. They seek buyout, recapitalization, and growth equity investments with significant business improvement potential and strong growth prospects.

SK Capital’s most frequently invested sectors include chemicals and life science. Since its inception, they have acquired over 50 companies and invested in 13 more. Their most significant exit (disclosed to date) was the trade sale of Perimeter Solutions to Broadridge Financial in 2021.

SK Capital boasts an experienced multidisciplinary team with significant operating and investment expertise in specialty materials, ingredients, and life science industries. The team excels at managing large complex businesses, offering diverse product lines with ease and improving performance over time; additionally, they boast an outstanding track record in driving growth and increasing shareholder value in companies they invest in.